Engineered immune cells take aim at Mesothelin-Positive tumors
Disease control
Stopped early
This trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to be…
Phase 1/2 • Sponsor: TCR2 Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC